Capital One upgraded Outlook Therapeutics to Overweight from Equalweight with a $5 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on OTLK:
- Outlook Therapeutics® Reports Financial Results for Fiscal Year 2023 and Reiterates ONS-5010 Clinical and Regulatory Path Forward in the U.S. and EU
- Outlook Therapeutics expects to resubmit ONS-5010 BLA by end of 2024
- Outlook Therapeutics announces anticipated milestones
- Outlook Therapeutics reports 2023 EPS (24c), consensus (24c)
- Outlook Therapeutics® Submits Special Protocol Assessment (SPA) to FDA for Non-Inferiority Study of ONS-5010